Paul White, MD
Hematology & Oncology · Coeur D Alene, IDNPI 1356607485
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,040 of the $2,522 with a category attached, or 80.9%. It is spread thinly across 26 manufacturers, the largest accounting for just 14.3% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2023 at $844 and has fallen 85.1% since, to $126 in 2025. That places this record below the midpoint for hematology & oncology clinicians in ID, where the typical reported total is $2,538.
Across 74 payments — averaging $34.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$361
- Astellas Pharma US Inc$309
- Janssen Scientific Affairs, LLC$212
- Genentech USA, Inc.$182
- Sanofi$176
- E.r. Squibb & Sons, L.L.C.$153
- plus $1K from 20 others
Across 2 payments — averaging $11,750 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Janssen Research & Development, LLC$24K
What the payments were for
- Consulting fees$1506%
- Food & beverage$2,04081%
- Education$33213%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 8 | $361 |
| Astellas Pharma US Inc | 4 | $309 |
| Janssen Scientific Affairs, LLC | 3 | $212 |
| Genentech USA, Inc. | 7 | $182 |
| Sanofi | 9 | $176 |
| E.r. Squibb & Sons, L.L.C. | 5 | $153 |
| Pharmacyclics LLC, An Abbvie Company | 4 | $129 |
| Seagen Inc. | 1 | $115 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $111 |
| Amgen | 5 | $104 |
| Bristol Myers Squibb | 4 | $88 |
| Jazz Pharmaceuticals Inc. | 1 | $81 |
| Johnson & Johnson | 4 | $72 |
| GSK | 1 | $66 |
| Beone Medicines USA, Inc. | 1 | $60 |
| Eisai Inc. | 2 | $37 |
| Sobi, Inc | 1 | $37 |
| Mirati Therapeutics, Inc. | 1 | $36 |
| AVEO Pharmaceuticals, Inc. | 2 | $35 |
| Blueprint Medicines Corporation | 2 | $32 |
| Pfizer | 2 | $30 |
| Merck | 1 | $25 |
| Sumitomo Pharma America, Inc. | 1 | $24 |
| Puma Biotechnology, Inc. | 1 | $18 |
| Myriad Genetic Laboratories, Inc. | 1 | $16 |
| CTI Biopharma Corp. | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$2,522 in reported general payments places this provider in the 45th percentile of 34 hematology & oncology providers in Idaho.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JakafiRuxolitinib Phosphate | 64 | $1,040,168 |
| ImbruvicaIbrutinib | 49 | $774,503 |
| BrukinsaZanubrutinib | 48 | $599,730 |
| PomalystPomalidomide | 22 | $516,123 |
| VenclextaVenetoclax | 35 | $506,011 |
| Darzalex FasproDaratumumab-Hyaluronidase-Fihj | 23 | $427,096 |
| TagrissoOsimertinib Mesylate | 22 | $358,430 |
| VerzenioAbemaciclib | 23 | $339,312 |
| XtandiEnzalutamide | 22 | $252,881 |
| RevlimidLenalidomide | 18 | $247,987 |
| KisqaliRibociclib Succinate | 17 | $236,922 |
| IbrancePalbociclib | 15 | $225,751 |
| LynparzaOlaparib | 11 | $184,983 |
| NubeqaDarolutamide | 13 | $161,948 |
| EliquisApixaban | 80 | $75,279 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $129 | $774,50349 claims |
| AstraZenecaTagrisso, Lynparza | $361 | $543,41333 claims |
| E.r. Squibb & Sons, L.L.C.Pomalyst | $153 | $516,12322 claims |
| PfizerIbrance, Eliquis | $30 | $301,03195 claims |
| Astellas Pharma US IncXtandi, Veozah | $309 | $259,48935 claims |
| Bristol Myers SquibbRevlimid | $88 | $247,98718 claims |
| Sumitomo Pharma America, Inc.Orgovyx | $24 | $31,99613 claims |
| Johnson & JohnsonXarelto | $72 | $22,31924 claims |
| Janssen Scientific Affairs, LLCAbiraterone Acetate | $212 | $10,42413 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 34 hematology & oncology providers in Idaho.
Other hematology & oncology in Coeur D Alene
- Andrew KominskyCoeur D Alene$13K
- David BartelsCoeur D Alene$11K
- Brian SamuelsCoeur D Alene$690
- Danko MartincicPost Falls$1.1M
- Bobby ChawlaCaldwell$1M
- Christian ShullIdaho Falls$150K
- Dane DicksonRexburg$21K
- Ian QureshiNampa$18K
- Nathan AdamsIdaho Falls$16K
- Maria Cervantes FullmerIdaho Falls$9K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.